
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1184977/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Endocannabinoid signaling in glioma. Glia, 2023, 71, 127-138.	2.5	6
2	Cannabinoid CB1 receptor gene inactivation in oligodendrocyte precursors disrupts oligodendrogenesis and myelination in mice. Cell Death and Disease, 2022, 13, .	2.7	6
3	Δ ⁹ â€Tetrahydrocannabinol promotes oligodendrocyte development and CNS myelination in vivo. Glia, 2021, 69, 532-545.	2.5	21
4	Cannabinoid Cancer Biology and Prevention. Journal of the National Cancer Institute Monographs, 2021, 2021, 99-106.	0.9	11
5	Identification of BiP as a CB ₁ Receptor-Interacting Protein That Fine-Tunes Cannabinoid Signaling in the Mouse Brain. Journal of Neuroscience, 2021, 41, 7924-7941.	1.7	14
6	Δ 9 â€Tetrahydrocannabinol promotes functional remyelination in the mouse brain. British Journal of Pharmacology, 2021, 178, 4176-4192.	2.7	11
7	BiP Heterozigosity Aggravates Pathological Deterioration in Experimental Amyotrophic Lateral Sclerosis. International Journal of Molecular Sciences, 2021, 22, 12533.	1.8	5
8	Cannabinoid-induced motor dysfunction <i>via</i> autophagy inhibition. Autophagy, 2020, 16, 2289-2291.	4.3	1
9	Endocannabinoid signalling in stem cells and cerebral organoids drives differentiation to deep layer projection neurons via CB1 receptors. Development (Cambridge), 2020, 147, .	1.2	9
10	Glucose metabolism links astroglial mitochondria to cannabinoid effects. Nature, 2020, 583, 603-608.	13.7	169
11	Possible therapeutic applications of cannabis in the neuropsychopharmacology field. European Neuropsychopharmacology, 2020, 36, 217-234.	0.3	24
12	Can Cannabis Cure Cancer?. JAMA Oncology, 2020, 6, 323.	3.4	8
13	Long-term hippocampal interneuronopathy drives sex-dimorphic spatial memory impairment induced by prenatal THC exposure. Neuropsychopharmacology, 2020, 45, 877-886.	2.8	51
14	Inhibition of fatty acid amide hydrolase prevents pathology in neurovisceral acid sphingomyelinase deficiency by rescuing defective endocannabinoid signaling. EMBO Molecular Medicine, 2020, 12, e11776.	3.3	13
15	Inhibition of striatonigral autophagy as a link between cannabinoid intoxication and impairment of motor coordination. ELife, 2020, 9, .	2.8	7
16	Priority Considerations for Medicinal Cannabis-Related Research. Cannabis and Cannabinoid Research, 2019, 4, 139-157.	1.5	21
17	Oral administration of the cannabigerol derivative VCE-003.2 promotes subventricular zone neurogenesis and protects against mutant huntingtin-induced neurodegeneration. Translational Neurodegeneration, 2019, 8, 9.	3.6	24
18	Astroglial monoacylglycerol lipase controls mutant huntingtin-induced damage of striatal neurons. Neuropharmacology, 2019, 150, 134-144.	2.0	15

#	Article	IF	CITATIONS
19	Therapeutic targeting of HER2–CB ₂ R heteromers in HER2-positive breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 3863-3872.	3.3	40
20	Pathway-Specific Control of Striatal Neuron Vulnerability by Corticostriatal Cannabinoid CB1 Receptors. Cerebral Cortex, 2018, 28, 307-322.	1.6	25
21	Singular Location and Signaling Profile of Adenosine A2A-Cannabinoid CB1 Receptor Heteromers in the Dorsal Striatum. Neuropsychopharmacology, 2018, 43, 964-977.	2.8	52
22	Targeting Glioma Initiating Cells with A combined therapy of cannabinoids and temozolomide. Biochemical Pharmacology, 2018, 157, 266-274.	2.0	75
23	Novel Nano-Liposome Formulation for Dry Eyes with Components Similar to the Preocular Tear Film. Polymers, 2018, 10, 425.	2.0	28
24	Cannabis for the Management of Cancer Symptoms: THC Version 2.0?. Cannabis and Cannabinoid Research, 2018, 3, 117-119.	1.5	15
25	Appraising the "entourage effect†Antitumor action of a pure cannabinoid versus a botanical drug preparation in preclinical models of breast cancer. Biochemical Pharmacology, 2018, 157, 285-293.	2.0	126
26	Optimization of a preclinical therapy of cannabinoids in combination with temozolomide against glioma. Biochemical Pharmacology, 2018, 157, 275-284.	2.0	44
27	Contribution of Altered Endocannabinoid System to Overactive mTORC1 Signaling in Focal Cortical Dysplasia. Frontiers in Pharmacology, 2018, 9, 1508.	1.6	8
28	GEINO 1402: A phase Ib dose-escalation study followed by an extension phase to evaluate safety and efficacy of crizotonib in combination with temozolomide (TMZ) and radiotherapy (RT) in patients with newly diagnosed glioblastoma (GB): Results of the dose-escalation phase Journal of Clinical Oncology, 2018, 36, 2054-2054.	0.8	1
29	Loss of Cannabinoid CB ₁ Receptors Induces Cortical Migration Malformations and Increases Seizure Susceptibility. Cerebral Cortex, 2017, 27, 5303-5317.	1.6	23
30	Cannabinoid Type-2 Receptor Drives Neurogenesis and Improves Functional Outcome After Stroke. Stroke, 2017, 48, 204-212.	1.0	58
31	Endocannabinoid Actions on Cortical Terminals Orchestrate Local Modulation of Dopamine Release in the Nucleus Accumbens. Neuron, 2017, 96, 1112-1126.e5.	3.8	90
32	A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington's disease. Journal of Neurology, 2016, 263, 1390-1400.	1.8	105
33	Sustained Gq-Protein Signaling Disrupts Striatal Circuits via JNK. Journal of Neuroscience, 2016, 36, 10611-10624.	1.7	12
34	Dihydroceramide accumulation mediates cytotoxic autophagy of cancer cells via autolysosome destabilization. Autophagy, 2016, 12, 2213-2229.	4.3	118
35	MicroRNA let-7d is a target of cannabinoid CB 1 receptor and controls cannabinoid signaling. Neuropharmacology, 2016, 108, 345-352.	2.0	23
36	Activation of the orphan receptor GPR55 by lysophosphatidylinositol promotes metastasis in triple-negative breast cancer. Oncotarget, 2016, 7, 47565-47575.	0.8	40

MANUEL GUZMÃIN

#	Article	IF	CITATIONS
37	Role of Cannabinoid Receptor CB2 in HER2 Pro-oncogenic Signaling in Breast Cancer. Journal of the National Cancer Institute, 2015, 107, djv077.	3.0	98
38	Endocannabinoids and Cancer. Handbook of Experimental Pharmacology, 2015, 231, 449-472.	0.9	45
39	Prenatal exposure to cannabinoids evokes long-lasting functional alterations by targeting CB ₁ receptors on developing cortical neurons. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 13693-13698.	3.3	120
40	High Prevalence of Diabetes and Prediabetes and Their Coexistence with Cardiovascular Risk Factors in a Hispanic Community. Journal of Immigrant and Minority Health, 2015, 17, 1002-1009.	0.8	25
41	CB ₁ Cannabinoid Receptor-Dependent Activation of mTORC1/Pax6 Signaling Drives Tbr2 Expression and Basal Progenitor Expansion in the Developing Mouse Cortex. Cerebral Cortex, 2015, 25, 2395-2408.	1.6	30
42	Early Social Enrichment Rescues Adult Behavioral and Brain Abnormalities in a Mouse Model of Fragile X Syndrome. Neuropsychopharmacology, 2015, 40, 1113-1122.	2.8	87
43	Chronic cannabinoid receptor stimulation selectively prevents motor impairments in a mouse model of Huntington's disease. Neuropharmacology, 2015, 89, 368-374.	2.0	24
44	TRIB3 suppresses tumorigenesis by controlling mTORC2/AKT/FOXO signaling. Molecular and Cellular Oncology, 2015, 2, e980134.	0.3	16
45	Cannabinoids. , 2015, , 777-782.		0
46	Cannabinoids. , 2015, , 1-5.		0
47	A restricted population of CB ₁ cannabinoid receptors with neuroprotective activity. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 8257-8262.	3.3	136
48	Tocilizumab en pacientes con artritis reumatoide activa y respuesta inadecuada a fármacos antirreumáticos modificadores de la enfermedad o antagonistas del factor de necrosis tumoral: subanálisis de los datos españoles de un estudio abierto cercano a la práctica clÃnica habitual. ReumatologÃa ClÃnica, 2014, 10, 94-100.	0.2	5
49	The endocannabinoid system controls food intake via olfactory processes. Nature Neuroscience, 2014, 17, 407-415.	7.1	229
50	Programming of neural cells by (endo)cannabinoids: from physiological rules to emerging therapies. Nature Reviews Neuroscience, 2014, 15, 786-801.	4.9	235
51	Design and Characterization of an Ocular Topical Liposomal Preparation to Replenish the Lipids of the Tear Film. Investigative Ophthalmology and Visual Science, 2014, 55, 7839-7847.	3.3	42
52	Targeting CB2-GPR55 Receptor Heteromers Modulates Cancer Cell Signaling. Journal of Biological Chemistry, 2014, 289, 21960-21972.	1.6	95
53	Association of Cigarette Smoking and Metabolic Syndrome in a Puerto Rican Adult Population. Journal of Immigrant and Minority Health, 2013, 15, 810-816.	0.8	27
54	Cannabinoid receptor signaling in progenitor/stem cell proliferation and differentiation. Progress in Lipid Research, 2013, 52, 633-650.	5.3	240

#	Article	IF	CITATIONS
55	The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system. International Journal of Neuropsychopharmacology, 2013, 16, 1407-1419.	1.0	225
56	The pseudokinase tribbles homologue-3 plays a crucial role in cannabinoid anticancer action. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2013, 1831, 1573-1578.	1.2	46
57	Drugâ€Eluting vs. Conventional Balloon for Side Branch Dilation in Coronary Bifurcations Treated by Provisional T Stenting. Journal of Interventional Cardiology, 2013, 26, 454-462.	0.5	27
58	Activation of the sympathetic nervous system mediates hypophagic and anxiety-like effects of CB ₁ receptor blockade. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 4786-4791.	3.3	115
59	Natural Cannabinoids Improve Dopamine Neurotransmission and Tau and Amyloid Pathology in a Mouse Model of Tauopathy. Journal of Alzheimer's Disease, 2013, 35, 525-539.	1.2	98
60	The Role of GPR55 in Cancer. , 2013, , 115-133.		1
61	A Pathogenic Mechanism in Huntington's Disease Involves Small CAG-Repeated RNAs with Neurotoxic Activity. PLoS Genetics, 2012, 8, e1002481.	1.5	161
62	Endocannabinoids via CB ₁ receptors act as neurogenic niche cues during cortical development. Philosophical Transactions of the Royal Society B: Biological Sciences, 2012, 367, 3229-3241.	1.8	76
63	Cannabinoids: A new hope for breast cancer therapy?. Cancer Treatment Reviews, 2012, 38, 911-918.	3.4	88
64	The CB ₁ Cannabinoid Receptor Drives Corticospinal Motor Neuron Differentiation through the Ctip2/Satb2 Transcriptional Regulation Axis. Journal of Neuroscience, 2012, 32, 16651-16665.	1.7	79
65	CB2 Cannabinoid Receptors Promote Neural Progenitor Cell Proliferation via mTORC1 Signaling. Journal of Biological Chemistry, 2012, 287, 1198-1209.	1.6	145
66	Towards the use of cannabinoids as antitumour agents. Nature Reviews Cancer, 2012, 12, 436-444.	12.8	303
67	A Combined Preclinical Therapy of Cannabinoids and Temozolomide against Glioma. Molecular Cancer Therapeutics, 2011, 10, 90-103.	1.9	238
68	Prospects for cannabinoid therapies in basal ganglia disorders. British Journal of Pharmacology, 2011, 163, 1365-1378.	2.7	98
69	Comparison of zotarolimus―versus everolimusâ€eluting stents in the treatment of coronary bifurcation lesions. Catheterization and Cardiovascular Interventions, 2011, 78, 1086-1092.	0.7	15
70	Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease. Brain, 2011, 134, 119-136.	3.7	178
71	Association between adiposity indices and cardiometabolic risk factors among adults living in Puerto Rico. Public Health Nutrition, 2011, 14, 1714-1723.	1.1	32
72	Stimulation of ALK by the growth factor midkine renders glioma cells resistant to autophagy-mediated cell death. Autophagy, 2011, 7, 1071-1073.	4.3	27

#	Article	IF	CITATIONS
73	Detecting Autophagy in Response to ER Stress Signals in Cancer. Methods in Enzymology, 2011, 489, 297-317.	0.4	24
74	A New Age for MAGL. Chemistry and Biology, 2010, 17, 4-6.	6.2	11
75	Endocannabinoids and cannabinoid analogues block cardiac hKv1.5 channels in a cannabinoid receptor-independent manner. Cardiovascular Research, 2010, 85, 56-67.	1.8	48
76	Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. Molecular Cancer, 2010, 9, 196.	7.9	156
77	TRB3 links ER stress to autophagy in cannabinoid antitumoral action. Autophagy, 2009, 5, 1048-1049.	4.3	68
78	Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. Journal of Clinical Investigation, 2009, 119, 1359-1372.	3.9	585
79	Cannabinoid receptor 1 is a potential drug target for treatment of translocation-positive rhabdomyosarcoma. Molecular Cancer Therapeutics, 2009, 8, 1838-1845.	1.9	46
80	Amphiregulin is a factor for resistance of glioma cells to cannabinoidâ€induced apoptosis. Glia, 2009, 57, 1374-1385.	2.5	37
81	The endocannabinoid system and the regulation of neural development: potential implications in psychiatric disorders. European Archives of Psychiatry and Clinical Neuroscience, 2009, 259, 371-382.	1.8	94
82	Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. Brain, 2009, 132, 3152-3164.	3.7	323
83	Down-regulation of tissue inhibitor of metalloproteinases-1 in gliomas: a new marker of cannabinoid antitumoral activity?. Neuropharmacology, 2008, 54, 235-243.	2.0	45
84	Cannabinoids Inhibit Glioma Cell Invasion by Down-regulating Matrix Metalloproteinase-2 Expression. Cancer Research, 2008, 68, 1945-1952.	0.4	161
85	The CB2 Cannabinoid Receptor Controls Myeloid Progenitor Trafficking. Journal of Biological Chemistry, 2008, 283, 13320-13329.	1.6	141
86	Endocannabinoid signaling controls pyramidal cell specification and long-range axon patterning. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 8760-8765.	3.3	263
87	Mechanisms of Control of Neuron Survival by the Endocannabinoid System. Current Pharmaceutical Design, 2008, 14, 2279-2288.	0.9	113
88	Endocannabinoid Functions in Neurogenesis, Neuronal Migration, and Specification. , 2008, , 237-256.		0
89	Targeting Cannabinoid Receptors in Brain Tumors. , 2008, , 361-374.		1
90	The CB1 Cannabinoid Receptor Mediates Excitotoxicity-induced Neural Progenitor Proliferation and Neurogenesis*. Journal of Biological Chemistry, 2007, 282, 23892-23898.	1.6	146

#	Article	IF	CITATIONS
91	Cannabinoids Induce Glioma Stem-like Cell Differentiation and Inhibit Gliomagenesis. Journal of Biological Chemistry, 2007, 282, 6854-6862.	1.6	116
92	Cannabinoid CB2 receptor: a new target for controlling neural cell survival?. Trends in Pharmacological Sciences, 2007, 28, 39-45.	4.0	331
93	The emerging functions of endocannabinoid signaling during CNS development. Trends in Pharmacological Sciences, 2007, 28, 83-92.	4.0	357
94	The Endocannabinoid System and Neurogenesis in Health and Disease. Neuroscientist, 2007, 13, 109-114.	2.6	107
95	Cannabinoids and Gliomas. Molecular Neurobiology, 2007, 36, 60-67.	1.9	82
96	Preface: Cannabinoids as New Tools for the Treatment of Neurological Disorders. Molecular Neurobiology, 2007, 36, 1-2.	1.9	2
97	Cannabinoid receptors as novel targets for the treatment of melanoma. FASEB Journal, 2006, 20, 2633-2635.	0.2	244
98	A Cannabinoid Quinone Inhibits Angiogenesis by Targeting Vascular Endothelial Cells. Molecular Pharmacology, 2006, 70, 51-59.	1.0	71
99	The CB2 cannabinoid receptor signals apoptosis via ceramide-dependent activation of the mitochondrial intrinsic pathway. Experimental Cell Research, 2006, 312, 2121-2131.	1.2	84
100	p8 Upregulation sensitizes astrocytes to oxidative stress. FEBS Letters, 2006, 580, 1571-1575.	1.3	20
101	The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells. Cancer Cell, 2006, 9, 301-312.	7.7	299
102	Endocannabinoids: A New Family of Lipid Mediators Involved in the Regulation of Neural Cell Development. Current Pharmaceutical Design, 2006, 12, 2319-2325.	0.9	86
103	Δ9-Tetrahydrocannabinol Inhibits Cell Cycle Progression in Human Breast Cancer Cells through Cdc2 Regulation. Cancer Research, 2006, 66, 6615-6621.	0.4	192
104	Cannabinoids Induce Apoptosis of Pancreatic Tumor Cells via Endoplasmic Reticulum Stress–Related Genes. Cancer Research, 2006, 66, 6748-6755.	0.4	302
105	Nonâ€psychoactive CB 2 cannabinoid agonists stimulate neural progenitor proliferation. FASEB Journal, 2006, 20, 2405-2407.	0.2	201
106	The Endocannabinoid System Promotes Astroglial Differentiation by Acting on Neural Progenitor Cells. Journal of Neuroscience, 2006, 26, 1551-1561.	1.7	225
107	Cold Exposure Stimulates Synthesis of the Bioactive Lipid Oleoylethanolamide in Rat Adipose Tissue. Journal of Biological Chemistry, 2006, 281, 22815-22818.	1.6	29
108	Prevention of Alzheimer's Disease Pathology by Cannabinoids: Neuroprotection Mediated by Blockade of Microglial Activation. Journal of Neuroscience, 2005, 25, 1904-1913.	1.7	670

#	Article	IF	CITATIONS
109	The endocannabinoid system drives neural progenitor proliferation. FASEB Journal, 2005, 19, 1704-1706.	0.2	291
110	Interleukin 12 (IL12B) and Interleukin 12 Receptor (IL12RB1) Gene Polymorphisms in Rheumatoid Arthritis. Human Immunology, 2005, 66, 710-714.	1.2	32
111	Cannabinoids and ceramide: Two lipids acting hand-by-hand. Life Sciences, 2005, 77, 1723-1731.	2.0	69
112	p38 MAPK is involved in CB2receptor-induced apoptosis of human leukaemia cells. FEBS Letters, 2005, 579, 5084-5088.	1.3	71
113	Cannabinoids Inhibit the Vascular Endothelial Growth Factor Pathway in Gliomas. Cancer Research, 2004, 64, 5617-5623.	0.4	220
114	Oleoylethanolamide Stimulates Lipolysis by Activating the Nuclear Receptor Peroxisome Proliferator-activated Receptor α (PPAR-α). Journal of Biological Chemistry, 2004, 279, 27849-27854.	1.6	295
115	Ketone body synthesis in the brain: possible neuroprotective effects. Prostaglandins Leukotrienes and Essential Fatty Acids, 2004, 70, 287-292.	1.0	127
116	Hypothesis: cannabinoid therapy for the treatment of gliomas?. Neuropharmacology, 2004, 47, 315-323.	2.0	70
117	Predictors and prognostic value of myocardial injury following stent implantation. International Journal of Cardiology, 2004, 97, 193-198.	0.8	31
118	Ceramide sensitizes astrocytes to oxidative stress: protective role of cannabinoids. Biochemical Journal, 2004, 380, 435-440.	1.7	54
119	Comparison of prognostic value of atrial fibrillation versus sinus rhythm in patients on long-term hemodialysis. American Journal of Cardiology, 2003, 92, 868-871.	0.7	116
120	Neurons on cannabinoids: dead or alive?. British Journal of Pharmacology, 2003, 140, 439-440.	2.7	25
121	Cannabinoids: potential anticancer agents. Nature Reviews Cancer, 2003, 3, 745-755.	12.8	616
122	Ought dialysis patients with atrial fibrillation be treated with oral anticoagulants?. International Journal of Cardiology, 2003, 87, 135-139.	0.8	76
123	Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. Journal of Clinical Investigation, 2003, 111, 43-50.	3.9	315
124	Inhibition of tumor angiogenesis by cannabinoids. FASEB Journal, 2003, 17, 1-16.	0.2	241
125	Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. Journal of Clinical Investigation, 2003, 111, 43-50.	3.9	165
126	The Endocannabinoid Anandamide Inhibits Neuronal Progenitor Cell Differentiation through Attenuation of the Rap1/B-Raf/ERK Pathway. Journal of Biological Chemistry, 2002, 277, 46645-46650.	1.6	212

#	Article	IF	CITATIONS
127	Mechanism of Extracellular Signal-Regulated Kinase Activation by the CB1 Cannabinoid Receptor. Molecular Pharmacology, 2002, 62, 1385-1392.	1.0	173
128	De novo-synthesized ceramide is involved in cannabinoid-induced apoptosis. Biochemical Journal, 2002, 363, 183.	1.7	145
129	De novo-synthesized ceramide is involved in cannabinoid-induced apoptosis. Biochemical Journal, 2002, 363, 183-188.	1.7	144
130	Cannabinoids Protect Astrocytes from Ceramide-induced Apoptosis through the Phosphatidylinositol 3-Kinase/Protein Kinase B Pathway. Journal of Biological Chemistry, 2002, 277, 36527-36533.	1.6	145
131	Possible Involvement of Cytoskeletal Components in the Control of Hepatic Carnitine Palmitoyltransferase I Activity. Advances in Experimental Medicine and Biology, 2002, 466, 43-52.	0.8	6
132	Cannabinoids and cell fate. , 2002, 95, 175-184.		148
133	The AMP-Activated Protein Kinase Is Involved in the Regulation of Ketone Body Production by Astrocytes. Journal of Neurochemistry, 2002, 73, 1674-1682.	2.1	110
134	Ceramide Signaling in Cannabinoid Action. Molecular Biology Intelligence Unit, 2002, , 125-132.	0.2	0
135	Ceramide: a new second messenger of cannabinoid action. Trends in Pharmacological Sciences, 2001, 22, 19-22.	4.0	115
136	Is there an astrocyte–neuron ketone body shuttle?. Trends in Endocrinology and Metabolism, 2001, 12, 169-173.	3.1	170
137	The AMP-activated protein kinase prevents ceramide synthesis de novo and apoptosis in astrocytes. FEBS Letters, 2001, 489, 149-153.	1.3	154
138	The CB ₁ Cannabinoid Receptor of Astrocytes Is Coupled to Sphingomyelin Hydrolysis through the Adaptor Protein Fan. Molecular Pharmacology, 2001, 59, 955-959.	1.0	98
139	Control of the cell survival/death decision by cannabinoids. Journal of Molecular Medicine, 2001, 78, 613-625.	1.7	207
140	The Stimulation of Ketogenesis by Cannabinoids in Cultured Astrocytes Defines Carnitine Palmitoyltransferase I as a New Ceramide-Activated Enzyme. Journal of Neurochemistry, 2001, 72, 1759-1768.	2.1	72
141	Adenosine monophosphate[ndash]activated protein kinase mediates the protective effects of ischemic preconditioning on hepatic ischemia-reperfusion injury in the rat. Hepatology, 2001, 34, 1164-1173.	3.6	158
142	Signaling at zero g: a comment. Trends in Biochemical Sciences, 2001, 26, 533.	3.7	1
143	Leptin Induces Mitochondrial Superoxide Production and Monocyte Chemoattractant Protein-1 Expression in Aortic Endothelial Cells by Increasing Fatty Acid Oxidation via Protein Kinase A. Journal of Biological Chemistry, 2001, 276, 25096-25100.	1.6	530
144	The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt. Biochemical Journal, 2000, 347, 369.	1.7	162

#	Article	IF	CITATIONS
145	The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt. Biochemical Journal, 2000, 347, 369-373.	1.7	215
146	Anti-tumoral action of cannabinoids: Involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nature Medicine, 2000, 6, 313-319.	15.2	610
147	The CB ₁ Cannabinoid Receptor Is Coupled to the Activation of c-Jun N-Terminal Kinase. Molecular Pharmacology, 2000, 58, 814-820.	1.0	186
148	De novoâ€synthesized ceramide signals apoptosis in astrocytes via extracellular signalâ€regulated kinase. FASEB Journal, 2000, 14, 2315-2322.	0.2	144
149	Influence of atrial fibrillation on the morbido-mortality of patients on hemodialysis. American Heart Journal, 2000, 140, 886-890.	1.2	150
150	Do Cytoskeletal Components Control Fatty Acid Translocation into Liver Mitochondria?. Trends in Endocrinology and Metabolism, 2000, 11, 49-53.	3.1	17
151	Metabolism of trans fatty acids by hepatocytes. Lipids, 1999, 34, 381-386.	0.7	24
152	Effects of cannabinoids on energy metabolism. Life Sciences, 1999, 65, 657-664.	2.0	63
153	Involvement of the cAMP/protein kinase A pathway and of mitogen-activated protein kinase in the anti-proliferative effects of anandamide in human breast cancer cells. FEBS Letters, 1999, 463, 235-240.	1.3	145
154	Loss of response of carnitine palmitoyltransferase I to okadaic acid in transformed hepatic cells. Biochemical Pharmacology, 1998, 56, 1485-1488.	2.0	4
155	î"9-Tetrahydrocannabinol induces apoptosis in C6 glioma cells. FEBS Letters, 1998, 436, 6-10.	1.3	248
156	Evidence that the AMP-activated protein kinase stimulates rat liver carnitine palmitoyltransferase I by phosphorylating cytoskeletal components. FEBS Letters, 1998, 439, 317-320.	1.3	40
157	Malonyl-CoA-independent Acute Control of Hepatic Carnitine Palmitoyltransferase I Activity. Journal of Biological Chemistry, 1998, 273, 21497-21504.	1.6	38
158	Involvement of Sphingomyelin Hydrolysis and the Mitogen-Activated Protein Kinase Cascade in the Δ ⁹ -Tetrahydrocannabinol-Induced Stimulation of Glucose Metabolism in Primary Astrocytes. Molecular Pharmacology, 1998, 54, 834-843.	1.0	189
159	Role of Carnitine Palmitoyltransferase I in the Control of Ketogenesis in Primary Cultures of Rat Astrocytes. Journal of Neurochemistry, 1998, 71, 1597-1606.	2.1	88
160	Involvement of Ca2+/calmodulin-dependent protein kinase II in the activation of carnitine palmitoyltransferase I by okadaic acid in rat hepatocytes. Biochemical Journal, 1997, 321, 211-216.	1.7	18
161	Control of Hepatic Fatty Acid Oxidation by 5′-AMP-Activated Protein Kinase Involves a Malonyl-CoA-Dependent and a Malonyl-CoA-Independent Mechanism. Archives of Biochemistry and Biophysics, 1997, 337, 169-175.	1.4	110
162	Studies on the Intracellular Localization of Acetyl-CoA Carboxylase. Biochemical and Biophysical Research Communications, 1997, 233, 253-257.	1.0	21

#	Article	IF	CITATIONS
163	Metabolic stimulation of mouse spleen lymphocytes by low doses of 9-tetrahydrocannabinol. Life Sciences, 1997, 60, 1709-1717.	2.0	15
164	Δ9-Tetrahydrocannabinol stimulates glucose utilization in C6 glioma cells. Brain Research, 1997, 767, 64-71.	1.1	33
165	Are Cytoskeletal Components Involved in the Control of Hepatic Carnitine Palmitoyltransferase I Activity?. Biochemical and Biophysical Research Communications, 1996, 224, 754-759.	1.0	21
166	Effect of different types of high carbohydrate diets on glycogen metabolism in liver and skeletal muscle of endurance-trained rats. European Journal of Applied Physiology and Occupational Physiology, 1996, 74, 91-99.	1.2	6
167	Effects of physical training on fatty acid metabolism in liver and skeletal muscle of rats fed four different high-carbohydrate diets. Journal of Nutritional Biochemistry, 1996, 7, 348-355.	1.9	8
168	Effects of anandamide on hepatic fatty acid metabolism. Biochemical Pharmacology, 1995, 50, 885-888.	2.0	18
169	Inhibition of carnitine palmitoyltransferase I by hepatocyte swelling. FEBS Letters, 1994, 344, 239-241.	1.3	21
170	Effects of lovastatin on hepatic fatty acid metabolism. Lipids, 1993, 28, 1087-1093.	0.7	17
171	Regulation of fatty acid oxidation in mammalian liver. Lipids and Lipid Metabolism, 1993, 1167, 227-241.	2.6	100
172	Okadaic acid stimulates carnitine palmitoyltransferase I activity and palmitate oxidation in isolated rat hepatocytes. FEBS Letters, 1991, 291, 105-108.	1.3	22
173	Treatment with anabolic steroids increases the activity of the mitochondrial outer carnitine palmitoyltransferase in rat liver and fast-twitch muscle. Biochemical Pharmacology, 1991, 41, 833-835.	2.0	28
174	Properties of the mitochondrial membrane and carnitine palmitoyltransferase I in the periportal and the perivenous zone of the liver. Biochemical Pharmacology, 1991, 41, 1987-1995.	2.0	17
175	Alterations in the Regulatory Properties of Hepatic Fatty Acid Oxidation and Carnitine Palmitoyltransferase I Activity after Ethanol Feeding and Withdrawal. Alcoholism: Clinical and Experimental Research, 1990, 14, 472-477.	1.4	15
176	Zonal heterogeneity of the effects of chronic ethanol feeding on hepatic fatty acid metabolism. Hepatology, 1990, 12, 1098-1105.	3.6	34
177	Simultaneous stimulation of fatty acid synthesis and oxidation in rat hepatocytes by vanadate. Archives of Biochemistry and Biophysics, 1990, 283, 90-95.	1.4	16
178	Ethanol increases the sensitivity of carnitine palmitoyltransferase I to inhibition by malonyl-CoA in short-term hepatocyte incubations. Lipids and Lipid Metabolism, 1989, 1002, 405-408.	2.6	8
179	Effects of ethanol feeding on hepatic lipid synthesis. Archives of Biochemistry and Biophysics, 1988, 267, 568-579.	1.4	50
180	Effects of ethanol feeding on the activity and regulation of hepatic carnitine palmitoyltransferase I. Archives of Biochemistry and Biophysics, 1988, 267, 580-588.	1.4	22

#	Article	IF	CITATIONS
181	Effects of endurance exercise on carnitine palmitoyltransferase I from rat heart, skeletal muscle and liver mitochondria. Lipids and Lipid Metabolism, 1988, 963, 562-565.	2.6	21
182	Short-term inhibition of carnitine palmitoyltransferase I activity in rat hepatocytes incubated with ethanol. Biochemical and Biophysical Research Communications, 1988, 154, 682-687.	1.0	11
183	Short-term regulation of carnitine palmitoyltransferase activity in isolated rat hepatocytes. Biochemical and Biophysical Research Communications, 1988, 151, 781-787.	1.0	44